Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
02 janv. 2018 07h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
20 déc. 2017 17h30 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
19 déc. 2017 10h16 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
08 déc. 2017 16h34 HE
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
13 nov. 2017 16h05 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
08 nov. 2017 21h38 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
02 déc. 2016 08h00 HE
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...
Apellis to Present Safety and Efficacy Data from Clinical Trials of APL-2 in PNH at December Scientific Meetings
21 nov. 2016 08h00 HE
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, announced today it will...